Intranasal esketamine for depression: Not so special K
Australasian Psychiatry August 1, 2022 Stephen Rosenman 2 citations
Background Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most research has been done, costs less than $20 per dose. Research shows that intranasal esketamine is less effective and has more unwanted effects than injected...